Shahrooz Eshaghian
Oncology | Hematology
2080 Century Park East
Suite 1005
Los Angeles, CA 90067
Suite 1005
Los Angeles, CA 90067
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Outcomes for unselected, newly diagnosed multiple myeloma patients.
Journal: Haematologica
Published: January 24, 2025
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Journal: Targeted oncology
Published: March 04, 2024
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
Journal: Targeted oncology
Published: August 09, 2023
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.
Journal: Cancer reports (Hoboken, N.J.)
Published: November 16, 2022
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
Journal: British journal of haematology
Published: September 01, 2022
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
Journal: Hematological oncology
Published: May 06, 2022
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Journal: Experimental hematology
Published: May 02, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Journal: Experimental hematology
Published: February 25, 2022
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Journal: Leukemia & lymphoma
Published: November 25, 2021
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination.
Journal: Clinical infection in practice
Published: October 22, 2021
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Journal: Leukemia
Published: June 14, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Journal: British journal of cancer
Published: April 25, 2021
Last Updated: 09/26/2026